Drug Delivery System in the Treatment of Diabetes Mellitus

Zhao, Ruichen; Lü, Zhiguo; Yang, Jun; Zhang, Liqun; Li, Yan; Zhang, Xin

doi:10.3389/fbioe.2020.00880

Cited by 50 publications

(32 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The set points of chemical equilibrium-based glucose-recognition technologies (relative to enzyme-or protein-based schemes) may be more amenable to optimisation than ConA systems were found to be. Polymer-based GRIs can, in principle, employ a variety of encapsulation chemistries, including polyethylene glycol (PEF), poly(N-vinyl-pyrrolidone) and succinyl-amidophenylglucopyranoside [31,74,85]. Whereas the matrices are impermeable to insulin during normoglycaemic or hypoglycaemic conditions, their permeability may increase as a result of physical changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration.…”

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

“…Whereas the matrices are impermeable to insulin during normoglycaemic or hypoglycaemic conditions, their permeability may increase as a result of physical changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration. Examples include matrices co-derivatised with PBA, other boronic acids [86][87][88] and dot-immobilised glucose ester-based crosslinks [74,85,89].…”

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

See 1 more Smart Citation

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

et al. 2021

View full text Add to dashboard Cite

Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper-or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulindelivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such 'smart' systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimise mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based 'closed-loop' systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin's conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.

show abstract

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

Section: Polymer-based Gri Systemsmentioning

confidence: 99%

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Gene therapy is one of the most promising treatment strategies for CVD [ 30 , 31 , 32 , 33 , 34 ], inherited or acquired, through targeting the causative genes engaged in the induction and progression of the disease. It works through replacing defective genes, silencing overexpressed ones or providing functional copies of specific therapeutic genes, thanks to DNA, RNA (siRNA, microRNA, mRNA), and antisense oligonucleotides (ASO) [ 35 ]. Back in the 1950s and 1960s, several attempts were made to directly transfect cells with DNA and RNA.…”

Section: Conventional and Novel Therapies To Treat Cvdmentioning

confidence: 99%

Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine

et al. 2021

View full text Add to dashboard Cite

While oral agents have been the gold standard for cardiovascular disease therapy, the new generation of treatments is switching to other administration options that offer reduced dosing frequency and more efficacy. The lymphatic network is a unidirectional and low-pressure vascular system that is responsible for the absorption of interstitial fluids, molecules, and cells from the peripheral tissue, including the skin and the intestines. Targeting the lymphatic route for drug delivery employing traditional or new technologies and drug formulations is exponentially gaining attention in the quest to avoid the hepatic first-pass effect. The present review will give an overview of the current knowledge on the involvement of the lymphatic vessels in drug delivery in the context of cardiovascular disease.

show abstract

“…With the rapid growth of nanobiotechnology, nanomaterials have become more and more clinically applicable for medical treatment [ 18 , 19 ]. These nanomaterials with a size of 10–500 nm are able to increase the therapeutic efficacy and reduce the toxicity of therapeutic drugs by encapsulating or conjugating them to form stabilized nanomedicines [ 20 , 21 ]. These nanomedicines selectively penetrate into tumor tissues and achieve controlled, efficient and sustained drug release.…”

Section: Introductionmentioning

confidence: 99%

Polysaccharide-based nanomedicines for cancer immunotherapy: A review

Zeng

Xiang

Sheng

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

Cancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by immunotherapeutics. However, direct administration of “naked” immunotherapeutic agents (such as nucleic acids, cytokines, adjuvants or antigens without delivery vehicles) often results in: (1) an unsatisfactory efficacy due to suboptimal pharmacokinetics; (2) strong toxic and side effects due to low targeting (or off-target) efficiency. To overcome these shortcomings, a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side effects. Polysaccharides are a family of natural polymers that hold unique physicochemical and biological properties, as they could interact with immune system to stimulate an enhanced immune response. Their structures offer versatility in synthesizing multifunctional nanocomposites, which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor tissues. This review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics.

show abstract

Drug Delivery System in the Treatment of Diabetes Mellitus

Cited by 50 publications

References 100 publications

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine

Polysaccharide-based nanomedicines for cancer immunotherapy: A review

Contact Info

Product

Resources

About